Deepak Sahasrabudhe is an Oncology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 113 publications with 2,245 citations (h-index 25); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 Elmwood Ave.
Rochester, NY 146420001
Telephone
585-275-5823Registry record last updated 28 Jun 2023.
Clinical trials
- S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Sponsor: SWOG Cancer Research Network
- Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Sponsor: University of Rochester
- Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
Sponsor: University of Rochester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stryker CorporationProgram year20251 payment
- Iovance Biotherapeutics, Inc.Program year20241 payment
- Exelixis Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58%Androgen Receptor Inhibitor20.2%Xtandi53%Bicalutamide47%Part D<11 patientsCytochrome P450 17A1 Inhibitor12.2%Abiraterone Acetate100%Part D≥13 patients+ 4 more classes in this area
Nervous system
19.4%Phenothiazine19.4%Prochlorperazine Maleate100%Part D≥58 patientsMetabolism & gastrointestinal
17.8%Corticosteroid17.8%Prednisone100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2005 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Louis Constine, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Edward Messing, MD
University of Rochester Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”